ISOFT SANIDAD SA

Their core work

ISOFT SANIDAD SA is a Spanish healthcare IT company based in Málaga that develops and provides digital health software solutions for clinical and hospital environments. In EU research projects, they contribute as a third-party provider — supplying software platforms, health data infrastructure, or clinical systems integration capabilities to research consortia rather than conducting research themselves. Their project record shows expertise in connecting clinical data systems with AI-driven research pipelines, particularly for oncology and haematology applications. They bring practical deployment experience to projects that require real-world health data interoperability and patient-facing digital tools.

What they specialise in

How they've shifted over time

ISOFT's two-project H2020 record shows a clear progression from patient-facing digital health tooling toward advanced genomic data infrastructure. Their earliest project (PERSIST, 2020) centred on interoperability, privacy compliance, and structured survivorship care plans — classic health IT territory. By 2021, GenoMed4ALL pulled them into multi-omics data processing and federated learning for haematological diseases, a technically more demanding domain. The trajectory points from "clinical software integrator" toward "privacy-preserving AI infrastructure provider" for precision medicine.

ISOFT is moving up the technical stack — from health record integration toward federated machine learning infrastructure for genomics, making them increasingly relevant for precision medicine consortia that need GDPR-compliant distributed AI.

How they like to work

ISOFT participates exclusively as a third party across all recorded projects, meaning they provide a defined service or resource rather than being a funded consortium member. This pattern is typical of software vendors who supply a platform or data access layer that the research team depends on but who are not themselves conducting experiments or analysis. Working with them likely means a service-level or licensing relationship rather than a co-investigator partnership.

Through just two projects, ISOFT has been embedded in consortia touching 41 unique partners across 16 countries — both projects (PERSIST and GenoMed4ALL) are large RIA consortia with pan-European membership. Their network reach is disproportionately large relative to their project count, reflecting the scale of the health research programmes they contribute to.

What sets them apart

ISOFT occupies a rare niche as a commercial health IT company that bridges production clinical software and EU-funded AI research — a combination that most pure research institutes cannot offer. Their third-party model means they bring real deployed systems (not prototypes) into projects, which is valuable for consortia that need clinical validation environments. For a consortium building a precision medicine or digital health platform that must eventually reach patients, ISOFT's practical deployment experience in the Spanish health system is a concrete asset.

Highlights from their portfolio

• GenoMed4ALL
  A 2021–2025 RIA project applying AI, multi-omics, and federated learning to haematological diseases — one of the more technically advanced H2020 digital-health programmes, and a signal of ISOFT's push into precision medicine infrastructure.
• PERSIST
  A 2020–2023 RIA project building AI-driven, patient-centered survivorship care plans for cancer patients, with explicit focus on interoperability and privacy compliance — ISOFT's foundational EU research engagement.